2. Search Result
Search Result
Isoforms Recommended: CDK13
Results for "

CDK13

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

5

Recombinant Proteins

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-151110
    PROTAC CDK12/13 Degrader-1

    		PROTACs CDK Cancer
    PROTAC CDK12/13 Degrader-1 (7f) is a highly selective cell cycle protein-dependent kinase CDK12/CDK13 dual degrader with the DC50 values of 2.2 nM and 2.1 nM, respectively. PROTAC CDK12/13 Degrader-1 has anti-proliferative activity and can be used in breast cancer research .
    PROTAC CDK12/13 Degrader-1
  • HY-151110A
    PROTAC CDK12/13 Degrader-1 TFA

    		PROTACs CDK Cancer
    PROTAC CDK12/13 Degrader-1 (7f) TFA is a highly selective cell cycle protein-dependent kinase CDK12/CDK13 dual degrader with the DC50 values of 2.2 nM and 2.1 nM, respectively. PROTAC CDK12/13 Degrader-1 TFA has anti-proliferative activity and can be used in breast cancer research .
    PROTAC CDK12/13 Degrader-1 TFA
  • HY-130250
    SR-4835
    10+ Cited Publications

    		 CDK Apoptosis Cancer
    SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13 (CDK12: IC50=99 nM, Kd=98 nM; CDK13: Kd=4.9 nM). SR-4835 acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death .
    SR-4835
  • HY-103618
    THZ531
    20+ Cited Publications

    		 CDK Cancer
    THZ531 is a selective and covalent inhibitor of both CDK12 and CDK13 with IC50s of 158 nM and 69 nM, respectively .
    THZ531
  • HY-80013
    THZ1
    Maximum Cited Publications
    80 Publications Verification

    		 CDK Cancer
    THZ1 is a selective and potent covalent CDK7 inhibitor with an IC50 of 3.2 nM. THZ1 also inhibits the closely related kinases CDK12 and CDK13 and downregulates MYC expression .
    THZ1
  • HY-80013A
    THZ1 Hydrochloride
    Maximum Cited Publications
    80 Publications Verification

    		 CDK Cancer
    THZ1 Hydrochloride is a selective and potent covalent CDK7 inhibitor with an IC50 of 3.2 nM. THZ1 Hydrochloride also inhibits the closely related kinases CDK12 and CDK13 and downregulates MYC expression .
    THZ1 Hydrochloride
  • HY-RS02359
    CDK13 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) CDK Others

    CDK13 Human Pre-designed siRNA Set A contains three designed siRNAs for CDK13 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CDK13 Human Pre-designed siRNA Set A
    CDK13 Human Pre-designed siRNA Set A
  • HY-RS02360
    Cdk13 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) CDK Others

    Cdk13 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdk13 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cdk13 Mouse Pre-designed siRNA Set A
    Cdk13 Mouse Pre-designed siRNA Set A
  • HY-RS02361
    Cdk13 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) CDK Others

    Cdk13 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdk13 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Cdk13 Rat Pre-designed siRNA Set A
    Cdk13 Rat Pre-designed siRNA Set A
  • HY-164553
    ZSQ836

    		Apoptosis CDK Cancer
    ZSQ836 is an orally active dual covalent inhibitor of CDK12/CDK13, with an EC50 value of 32 nM against CDK12. ZSQ836 can induce apoptosis and exhibit anticancer activity in vivo. ZSQ836 can be used in the study of ovarian cancer .
    ZSQ836
  • HY-112626
    CDK12-IN-2

    		CDK Cancer
    CDK12-IN-2 is a potent, selective and nanomolar CDK12 inhibitor (IC50=52 nM) with good physicochemical properties. CDK12-IN-2 is also a strong CDK13 inhibitor due to CDK13 is the closest homologue of CDK12. CDK12-IN-2 shows excellent kinase selectivity for CDK12 over CDK2, 9, 8, and 7. CDK12-IN-2 inhibits the phosphorylation of Ser2 in the C-terminal domain of RNA polymerase II. CDK12-IN-2 can be used an excellent chemical probe for functional studies of CDK12 .
    CDK12-IN-2
  • HY-168556
    YJ9069

    		CDK PROTACs DNA/RNA Synthesis Cancer
    YJ9069 is a selective CDK12/CDK13 PROTAC degrader with an IC50 of 22.22 nM for in VCaP cells. CDK12/13 degradation rapidly triggers gene-length-dependent transcriptional elongation defects, leading to DNA damage and cell-cycle arrest. YJ9069 effectively inhibits proliferation in subsets of prostate cancer cells and significantly suppresses prostate tumor growth .
    YJ9069
  • HY-168555
    YJ1206

    		CDK PROTACs Apoptosis Cancer
    YJ1206 is an orally active, selective CDK12/CDK13 PROTAC degrader with an IC50 of 12.55 nM for in VCaP cells. YJ1206 increases DNA damage, induces apoptosis, and promotes tumor regression in orthotopic WA74 patient-derived xenograft (PDX) mice models of resistant prostate cancer. YJ1206 suppresses tumor growth in vivo in conjunction with AKT pathway inhibitors .
    YJ1206
  • HY-116871
    YKL-1-116

    		CDK Cancer
    YKL-1-116 is a selective and covalent inhibitor of Cdk7. YKL-1-116 does not target Cdk9, Cdk12, or Cdk13. YKL-1-116 is more potent than THZ1 (HY-80013) toward both Cdk7 WT and Cdk7 as, although Cdk7 as is relatively resistant to this compound as well .
    YKL-1-116
  • HY-149819
    CDK/HDAC-IN-3

    		HDAC CDK Cancer
    CDK/HDAC-IN-3 is an orally active HDACs/CDKs dual inhibitor. CDK/HDAC-IN-3 has potent and selective inhibition of CDK9, CDK12, CDK13, HDAC1, HDAC2 and HDAC3 with IC50 values of 98.32 nM, 98.85 nM, 100 nM, 62.12 nM, 93.28nM and 82.87 nM. CDK/HDAC-IN-3 can be used for the acute myeloid leukemia (AML) .
    CDK/HDAC-IN-3
  • HY-101257
    YKL-5-124
    5+ Cited Publications

    		 CDK Cancer
    YKL-5-124 is a potent, selective, irreversible and covalent CDK7 inhibitor with IC50s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively. YKL-5-124 is >100-fold greater selective for CDK7 than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status .
    YKL-5-124
  • HY-101257B
    YKL-5-124 TFA
    5+ Cited Publications

    		 CDK Cancer
    YKL-5-124 TFA is a potent, selective, irreversible and covalent CDK7 inhibitor with IC50s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively. YKL-5-124 TFA is >100-fold greater selective for CDK7 than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 TFA induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status .
    YKL-5-124 TFA
  • HY-148065
    FMF-06-098-1

    		PROTACs Cancer
    FMF-06-098-1 is a multitargeted depressant. FMF-06-098-1 can be used to target degradation kinases which degrades AAK1, AΒL2, AURKA, AURKB, BUBIB, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDk6, CDK7, CDK9, CHEK1, CSNKID, EPHA1, PER, FGFR1, GAK, IRAK4, ITK, LIMK2, MAP4K2, MAP4K3, MAPK6, MAPK7, MARK4, MELK, PKN3, PLK4, PRKAA1, PTK2, PTK6, RPS6KA4, S1K2, STK35, TNK2, UHMK1, ULK1, and WEE1 .
    FMF-06-098-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: